Evidence map›Paper›PMID 35829830›Full record

ArticleMolecular neurobiology2022

The mGlu

Wilber Romero-Fernandez, Jaume J Taura, René A J Crans, Marc Lopez-Cano, Ramon Fores-Pons, Manuel Narváez, Jens Carlsson, Francisco Ciruela, Kjell Fuxe, Dasiel O Borroto-Escuela

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Wilber Romero-FernandezDepartment of Cell and Molecular Biology, Science for Life Laboratory, Uppsala Univesity, 75124, Uppsala, Sweden.
Jaume J TauraPharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
René A J CransPharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Marc Lopez-CanoPharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Ramon Fores-PonsDivision of Cellular and Molecular Neurochemistry, Department of Neuroscience, Karolinska Institutet, Biomedicum (B0851), Solnavägen 9, 17165, Stockholm, Sweden.
Manuel NarváezFacultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Málaga, Spain.
Jens CarlssonDepartment of Cell and Molecular Biology, Science for Life Laboratory, Uppsala Univesity, 75124, Uppsala, Sweden.
Francisco CiruelaPharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. fciruela@ub.edu.
Kjell FuxeDivision of Cellular and Molecular Neurochemistry, Department of Neuroscience, Karolinska Institutet, Biomedicum (B0851), Solnavägen 9, 17165, Stockholm, Sweden. Kjell.Fuxe@ki.se.
Dasiel O Borroto-EscuelaDivision of Cellular and Molecular Neurochemistry, Department of Neuroscience, Karolinska Institutet, Biomedicum (B0851), Solnavägen 9, 17165, Stockholm, Sweden. dasiel.borroto.escuela@ki.se.
Karolinska Institutet · SEBellvitge University Hospital · ESScience for Life Laboratory · SEInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Investigación Biomédica de Málaga · ESUniversitat de Barcelona · ES

Funding

Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya 2017SGR1604Hjärnfonden F02018-0286Hjärnfonden F02019-0296Junta de Andalucía EMERGIA 2020-39318Stiftelsen Olle Engkvist Byggmästare 2019Stiftelsen Olle Engkvist Byggmästare 2021Vetenskapsrådet 2017- 4676Vetenskapsrådet 62X-00715-50-3
6 · The paper itself

Abstract

The adenosine A

Indexed as

DopamineParkinson DiseaseAdenosineAnimalsCatalepsyHaloperidolHEK293 CellsHumansMiceProtein SubunitsRatsReceptor, Adenosine A2AReceptors, Dopamine D2AdenosineDopamineHaloperidolProtein SubunitsReceptor, Adenosine A2AReceptors, Dopamine D2Adenosine A2A receptorAllosteric modulationDopamine D2 receptorHeteroreceptor complexMetabotropic glutamate receptor 5Receptor-receptor interaction

Identifiers

PMID35829830
PMCPMC9463353
OpenAlexW4285396154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.